AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01730313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00896831
Drug: L-ornithine-L-aspartate
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
Trial: NCT00896831
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 5 g (1 sachet) three times per day for 60 days
Trial: NCT00041509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo, oral, BID for 28 days
Trial: NCT04132479
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg taken orally every 12 hours for 5 days
Trial: NCT00363740
Drug: GW685698X Aqueous Nasal Spray
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00624208
Drug: saline and saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline and saline
Trial: NCT04132479
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg taken orally every 12 hours for 14 days
Trial: NCT01883167
Drug: RDEA3170 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDEA3170 10 mg once daily (qd)
Trial: NCT01883167
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo qd
Trial: NCT04587453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Trial: NCT00324792
Drug: intensive insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03136198
Drug: Intravenous Loop Diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV loop diuretic
Trial: NCT03136198
Drug: Vasodilator
RxNorm normalized name: Vasodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, topical, or SL Vasodilator
Trial: NCT00747175
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
Trial: NCT00747175
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration of oral suspension to a tolerable dose, 1 month treatment
Trial: NCT02114697
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
Trial: NCT02647983
Drug: Hyperpolarized Pyruvate (13C) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
Trial: NCT00705419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
Trial: NCT01072942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TID for 10 days
Trial: NCT03907215
Drug: ACT541468
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg; film-coated tablet for oral use
Trial: NCT03907215
Drug: ACT541468 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet for oral use
Trial: NCT03588338
Drug: Perfalgan
RxNorm normalized name: PERFALGAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For postoperative pain
Trial: NCT01632709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling
Trial: NCT03335371
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2: Participants will receive Placebo oral tablets for 12 weeks
Trial: NCT01923077
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: usual care with Simvastatin
Trial: NCT01923077
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
Trial: NCT01969357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets(n=4),once daily for 84 days
Trial: NCT01969357
Drug: 50 mg SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
Trial: NCT00683137
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
Trial: NCT00683137
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
Trial: NCT00683137
Drug: valdecoxib/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
Trial: NCT01551173
Drug: Fluvastatin sodium
RxNorm normalized name: Fluvastatin Sodium
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin sodium Extended Release Tablets 80mg
Trial: NCT03860688
Drug: TED + glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
Trial: NCT03569033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matching gefapixant will be administered orally.
Trial: NCT00765557
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
Trial: NCT03295084
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose Escalation
Trial: NCT00000371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day of placebo by mouth
Trial: NCT03056248
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
Trial: NCT01976208
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01426529
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A hormone that is normally present in your body, which regulates your blood pressure.
Trial: NCT00617526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01200472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules identical to apremilast
Trial: NCT04010799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - Part I - SAD Placebo Part II - MAD
Trial: NCT04500522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Trial: NCT03108690
Drug: Continuous infusion of beta-lactam antibiotics .
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam antibiotic will be administered as continous infusion.
Trial: NCT06023797
Drug: Neoadjuvant immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
Trial: NCT00455871
Drug: reduced fluence photodynamic therapy with Visudyne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reduced fluence photodynamic therapy with visudyne
Trial: NCT00990405
Drug: Lansoprzole+Amoxicillin+Clarithromycin
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
Trial: NCT01276782
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is FDA approved drug for thyroid disease
Trial: NCT01170442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally, daily for six months
Trial: NCT01979965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy for three months
Trial: NCT02226328
Drug: Midazolam and Fentanyl sedation
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191009
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01575054
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
Trial: NCT02473809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT00469586
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Trial: NCT02929693
Drug: Yiqi-yangyin-jiedu decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
Trial: NCT02929693
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
Trial: NCT04595136
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NS via nebulization
Trial: NCT01372150
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
Trial: NCT01372150
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
Trial: NCT01617590
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once
Trial: NCT00284323
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004152
Drug: iodinated contrast dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00648804
Drug: Zofran ODT® Tablets 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg, single dose fed
Trial: NCT04585321
Drug: Diclofenac Sodium 140mg Medicated Plaster
RxNorm normalized name: diclofenac sodium Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.
Trial: NCT04585321
Drug: Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day.
Trial: NCT01292161
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab 210 mg, 630 mg, daily, six months.
Trial: NCT00489203
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00489203
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given after transplant
Trial: NCT02377336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GS-6615 tablets administered orally
Trial: NCT02702960
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
Trial: NCT01224132
Drug: probiotic ® pur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
Trial: NCT04488575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT01101178
Drug: Reformulated OXY (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 80-mg tablet x 1 dose taken with food.
Trial: NCT01101178
Drug: Original OxyContin® (OXY) (oxycodone HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
Trial: NCT00858988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 7 consecutive days
Trial: NCT00944554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given twice a day or five weeks.
Trial: NCT00265733
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00217451
Drug: Fosmidomycin-clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00474760
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
Trial: NCT02846324
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules which contain GBT440 drug substance in Swedish orange
Trial: NCT02846324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00928083
Drug: OZ439 400mg aqueous dispersion
RxNorm normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01937299
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo comparator
Trial: NCT00928083
Drug: OZ439 800mg aqueous dispersion
RxNorm normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00091858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Q4W
Trial: NCT03167918
Drug: Calcium Dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gave each patient 0.5 g bid，
Trial: NCT03167918
Drug: Xuefuzhuyu Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gave each patient100 ml bid，po
Trial: NCT03167918
Drug: Xuefuzhuyu Decoction & Calcium dobesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
Trial: NCT00928083
Drug: OZ439 1600mg aqueous dispersion
RxNorm normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00928083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00928083
Drug: OZ439 200mg aqueous dispersion
RxNorm normalized name: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00952783
Drug: Lesion count
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Trial: NCT02532764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT00003399
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00926406
Drug: lead chelation therapy
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with lead poisoning (BLL\> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL \< 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
Trial: NCT02584140
Drug: Daily Oral PrEP
RxNorm normalized name: Daily Hist Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
Trial: NCT01695109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl, 0.2 ml
Trial: NCT02402166
Drug: SPD489
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
Trial: NCT02635243
Drug: SAR438544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Trial: NCT04032548
Drug: Placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Trial: NCT00487227
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00487227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03331042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
Trial: NCT00942851
Drug: Acetyl-Hexapeptide Topical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH-8 containing topical treatment
Trial: NCT00942851
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment NOT containing AH-8
Trial: NCT00720759
Drug: D-cycloserine + distributed treatment
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session